.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Predict branded drug patent expiration
  • Uncover prior art in expired and abandoned patents

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Baxter
AstraZeneca
Dow
Medtronic
Farmers Insurance
Queensland Health
Cantor Fitzgerald
US Army
Julphar
Harvard Business School

Generated: June 27, 2017

DrugPatentWatch Database Preview

Claims for Patent: 5,817,655

« Back to Dashboard

Claims for Patent: 5,817,655

Title: Methods of treatment using a thieno-benzodiazepine
Abstract:2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno -[2,3-b][1,5]benzodiazepine, or an acid salt thereof, has pharmaceutical properties, and is of particular use in the treatment of disorders of the central nervous system. The compound has the following structure: ##STR1##
Inventor(s): Chakrabarti; Jiban Kumar (Camberley, GB2), Hotten; Terrence Micharl (Farnborough, GB2), Tupper; David Edward (Reading, GB2)
Assignee: Eli Lilly and Company (Indianapolis, IN) Eli Lilly and Company Limited (Basingstoke, GB2)
Application Number:08/748,292
Patent Claims: 1. A method of treating a patient suffering from or susceptible to a psychosis selected from the group consisting of Delirium; Organic Delusional Disorder; Multi-infarct Dementia, With Delirium; Multi-infarct Dementia, With Delusions; Major Depression, Recurrent With Psychotic Features; and Organic Hallucinosis, comprising administering to the patient an amount of 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno-[2,3-b][1,5]benzodiazepine, or an acid addition salt thereof, that is effective to treat the psychosis.

2. A method of claim 1 wherein the effective amount is from 1 to 20 mg per day of 2-methyl-4-(4-methyl -1-piperazinyl)-10H-thieno-[2,3-b][1,5]benzodiazepine, or an acid addition salt thereof.

3. A method for treating a patient suffering from or susceptible to a psychosis selected from the group consisting of Delirium; Psychotic Disorder Due to a Medical Condition, With Delusions; Psychotic Disorder Due to a Medical Condition, With Hallucinations; Vascular Dementia, With Delirium; Vascular Dementia, With Delusions; and Severe Recurrent Major Depressive Disorder With Psychotic Features; comprising administering to the patient an amount of 2-methyl -4-(4-methyl-1-piperazinyl)-10H-thieno-[2,3-b][1,5]benzodiazepine, or an acid addition salt thereof, that is effective to treat the psychosis.

4. A method of claim 3 wherein the effective amount is from 1 to 20 mg per day.

5. A method for treating a patient suffering from the psychotic condition called Primary Degenerative Dementia of the Alzheimer Type, Presenile Onset, With Delusions, comprising administering to the patient an amount of 2-methyl -4-(4-methyl-1-piperazinyl)-10H-thieno-[2,3-b][1,5]benzodiazepine, or an acid addition salt thereof, that is effective to treat the condition.

6. The method of claim 5 wherein the effective amount is from 1 to 20 mg per day.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Accenture
Johnson and Johnson
US Department of Justice
Baxter
Daiichi Sankyo
Federal Trade Commission
McKinsey
Queensland Health
Dow
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot